inezetamab (AMG994) / Amgen, BeOne Medicines - LARVOL DELTA

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=11 | Completed | Sponsor: Amgen | Active, not recruiting ➔ Completed | Trial completion date: Sep 2023 ➔ Jun 2023

Combination therapy • Metastases • Monotherapy • Trial completion • Trial completion date • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • MSLN

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=11 | Active, not recruiting | Sponsor: Amgen | Trial completion date: Aug 2024 ➔ Sep 2023 | Trial primary completion date: Feb 2024 ➔ Jun 2023

Combination therapy • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • MSLN

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=11 | Active, not recruiting | Sponsor: Amgen | Trial completion date: Mar 2023 ➔ Aug 2024 | Trial primary completion date: Jan 2023 ➔ Feb 2024

Combination therapy • Monotherapy • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • MSLN

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=11 | Active, not recruiting | Sponsor: Amgen | Recruiting ➔ Active, not recruiting | N=214 ➔ 11 | Trial completion date: Aug 2025 ➔ Mar 2023 | Trial primary completion date: Feb 2025 ➔ Jan 2023

Combination therapy • Enrollment change • Enrollment closed • Monotherapy • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • MSLN

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=214 | Recruiting | Sponsor: Amgen | Trial primary completion date: Aug 2025 ➔ Feb 2025

Combination therapy • Monotherapy • Trial primary completion date • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • MSLN